Figure 2: Colchicine increases VSVΔ51 spread and oncolytic activity in resistant syngeneic and transgenic tumour models. | Nature Communications

Figure 2: Colchicine increases VSVΔ51 spread and oncolytic activity in resistant syngeneic and transgenic tumour models.

From: Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing

Figure 2

(a) Human colon carcinoma HT29 cells were established in nude mice. Ten days later, mice were treated with colchicine, MG-1, a combination of MG-1 and colchicine or with PBS only. Tumour volume was monitored for each group and average tumour volumes are shown (N=4–5). Error bars correspond to the s.e. (b) 4T1 tumour-bearing syngeneic mice were treated with VSVΔ51-luciferase or PBS, and colchicine or vehicle and luminescence monitored after 24 h. (c) 4T1 tumours (N=5) from mice treated as in b were harvested at the indicated times and titred by plaque assay (*P<0.05, t-test; ND=not detected). (d) 4T1 tumour-bearing syngeneic mice were treated with VSVΔ51, vinorelbine, a combination of VSVΔ51 and vinorelbine or PBS (N=10 per group). Survival was monitored over time. Log-rank test indicates that the combined treatment is significantly prolonged over virus alone (*P=0.024) or drug alone (**P=0.0082). (e) tgMISSIIR-TAg transgenic mice were treated with VSVΔ51-GM-CSF (n=11), PBS (n=7) colchicine (n=11) or VSVΔ51-GM-CSF and colchicine (n=10). Survival was monitored over time. Log-rank test indicates that the combined treatment is significantly prolonged over colchicine (*P=0.0082) and VSVΔ51-GM-CSF (**P=0.0007) alone.

Back to article page